Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates

被引:56
作者
Kim, SK
Lee, EH
Vaishali, B
Lee, S
Lee, YK
Kim, CY
Moon, HT
Byun, Y
机构
[1] Gwangju Inst Sci & Technol, Dept Mat Sci & Engn, Ctr Coll & Macromol Therapy, Kwangju 500712, South Korea
[2] Mediplex Corp, Seoul 135729, South Korea
[3] Korea Res Inst Chem Technol, Toxicol Res Ctr, Taejon 305600, South Korea
关键词
low molecule weight heparin; oral delivery; deoxycholic acid; microemulsion; tricaprylin;
D O I
10.1016/j.jconrel.2005.03.018
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Heparin is available to patients only by parenteral administrations due to its low oral bioavailability. For the oral delivery of low molecular weight heparin (LMWH), LMWH-DOCA was synthesized by chemical conjugation of LMWH and deoxycholic acid (DOCA) and this conjugate was formulated in a microemulsion system. The coupling ratios of DOCA to LMWH for LD I and LD2 were 1.33 and 2.37, respectively. The microemulsion was composed of tricaprylin, surfactant mixture (Tween (R) 80 and Span 9 20) and LMWH-DOCA in water, and their volume ratio was 5:3: 1: 1. Pharmacokinetic parameters of LMWH were not significantly changed by conjugation with DOCA; however, when LMWH-DOCA in tricaprylin microemulsion was orally administered in mice, its bioavailability was increased up to 1.5%. Furthermore, the enhancing effect of the conjugated DOCA in the tricaprylin microemulsion on the absorption of LMWH in the intestine was more significantly increased in monkey than in mice. Since the tricaprylin microemulsion could dissolve LMWH-DOCA, this formulation could maximize the enhancing effect of the conjugated DOCA on the absorption of LMWH in the intestine. Finally, it was expected that 20 mg/kg of LMWH-DOCA in the tricaprylin microemulsion was enough to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:32 / 42
页数:11
相关论文
共 32 条
[1]   Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. [J].
Breddin, HK ;
Hach-Wunderle, V ;
Nakov, R ;
Kakkar, VV .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (09) :626-631
[2]  
COUVREUR P, 1996, FORM POORL AV DRUGS
[3]   NEW HEPARIN COMPLEXES ACTIVE BY INTESTINAL-ABSORPTION - I-MULTIPLE ION-PAIRS WITH BASIC ORGANIC-COMPOUNDS [J].
DALPOZZO, A ;
ACQUASALIENTE, M ;
GERON, MR ;
ANDRIUOLI, G .
THROMBOSIS RESEARCH, 1989, 56 (01) :119-124
[4]   ORAL BIOAVAILABILITY OF HEPARIN USING A NOVEL DELIVERY SYSTEM [J].
DUNN, JM ;
HOLLISTER, AS .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1995, 56 (08) :738-745
[5]   Sterol carrier protein 2 participates in hypersecretion of biliary cholesterol during gallstone formation in genetically gallstone-susceptible mice [J].
Fuchs, M ;
Lammert, F ;
Wang, DQH ;
Paigen, B ;
Carey, MC ;
Cohen, DE .
BIOCHEMICAL JOURNAL, 1998, 336 :33-37
[6]  
Gallus A S, 1990, Baillieres Clin Haematol, V3, P651, DOI 10.1016/S0950-3536(05)80023-X
[7]  
GATTEFOSSE SA, 1998, MICROEMULSIONS FORM
[8]   Orally administered heparin for preventing deep venous thrombosis [J].
Gonze, MD ;
Manord, JD ;
Leone-Bay, A ;
Baughman, RA ;
Garrard, CL ;
Sternbergh, WC ;
Money, SR .
AMERICAN JOURNAL OF SURGERY, 1998, 176 (02) :176-178
[9]   Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism [J].
Grau, E ;
Tenias, JM ;
Real, E ;
Medrano, J ;
Ferrer, R ;
Pastor, E ;
Selfa, S .
AMERICAN JOURNAL OF HEMATOLOGY, 2001, 67 (01) :10-14
[10]   Prevention of venous thromboembolism in pregnancy [J].
Greer, IA .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2003, 16 (02) :261-278